BioPharma Drug Discovery
Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy impr...
April 30, 2026 | News
Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of the SELUTION SLR™ PTA Drug...
April 29, 2026 | News
The collaboration brings together consulting, device agnostic testing, and drug delivery expertise to help pharmaceutical and biotech companies reduce risk...
April 29, 2026 | News
Expanding HanchorBio's data-enabled approach from molecule design to portfolio and market insight -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stag...
April 27, 2026 | News
Regulatory Filing in Japan Planned Following Clinical Trial Completion – Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura...
April 27, 2026 | News
Everest Medicines announced that the first-in-human (FIH) clinical trial data of EVM16, a proprietary personalized mRNA cancer vaccine, were presen...
April 24, 2026 | News
ImmunoForge's LMT15 Platform combines high BBB permeability with proprietary long-acting ELP technology Technology excellence validated by winning first...
April 23, 2026 | News
Leinco Technologies, a leader in antibody and protein development, and CellCarta, a global provider of precision medicine laboratory services, are ple...
April 22, 2026 | News
With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one...
April 22, 2026 | News
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its wholly-owned subsidiary, T-m...
April 22, 2026 | News
Orthogon Therapeutics announced the closing of an $11 million follow-on financing, bringing the total capital raised to $36 million. The financing will ena...
April 21, 2026 | News
First-in-human study of EPI-326 will evaluate the company’s lead tissue-selective EGFR degrader in patients with NSCLC and HNSCC with potential to ...
April 21, 2026 | News
SYNTHBODY™ introduces a new class of “smart drugs”: protein therapeutics with built-in, multi-layered logic gates that actively chang...
April 20, 2026 | News
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that 18F-FD4 (R&D code: SST0...
April 16, 2026 | News
Most Read
Bio Jobs
News
Editor Picks